[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"incontinence-urge\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:incontinence-urge":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,47,73],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100467095","phase-4-treating-incontinence-for-underlying-mental-and-physical-health-100467095",false,"NCT05362292","TReating Incontinence for Underlying Mental and Physical Health","Cognitive, Urinary, and Functional Trajectories of Older Women Using Pharmacologic Treatment Strategies for Urgency Incontinence","TRIUMPH","Inclusion Criteria:\n\n* Aged 60 years or older at the time of enrollment\n* Female sex at birth, without surgical or hormonal gender re-assignment therapy\n* Able to walk to the bathroom and use the toilet without assistance\n* Report urinary incontinence starting at least 3 months prior to screening\n* Report that at least half of incontinence episodes occur with a sudden or strong sensation of urgency\n* Report 2 or more urgency incontinence episodes over a 7-day period\n* Willing to provide informed consent and adhere to study procedures throughout the length of the study\n\nExclusion Criteria:\n\n* Prior clinician diagnosis of dementia, or a Montreal Cognitive Assessment (MOCA) score of 17 or lower on screening cognitive evaluation\n* Current use of anticholinergic, beta-3-adrenergic agonist, or other medication designed to improve urgency incontinence symptoms, or use in the past 1 month\n* Initiation, discontinuation, or dose change of dementia medications (such as donepezil, galantamine, memantine, rivastigmine) in the past 1 month (but candidates on stable doses are eligible)\n* Initiation, discontinuation, or dose change of other drugs with strong anticholinergic effects (based on the Beers List) in the past 1 month (but candidates on stable doses are eligible)\n* Initiation, discontinuation, or dose change of other drugs that can affect urinary frequency, including diuretics, in the past 1 month (but candidates on stable doses are eligible)\n* Current urinary tract infection (UTI) based on screening urinalysis and culture (but candidates can re-present for re-screening after undergoing treatment for UTI)\n* History of allergy or sensitivity to either of the study medications or an ingredient in the placebo or study medication capsule\n* Severe hepatic impairment (Child-Pugh score B or greater) or renal impairment (creatinine clearance \\\u003C30 mL\u002Fmin) as a contraindication to both study medications\n* Current bladder obstruction or urinary retention (defined by symptoms suggesting difficulty emptying the bladder in addition to postvoid residual urine volume greater than 150 cc by portable bladder ultrasound)\n* Uncontrolled hypertension (based on measured systolic blood pressure greater than 180 or diastolic blood pressure greater than 110 mmHg) as a contraindication to beta-3-adrenergic therapy\n* Self-reported history of gastric retention, uncontrolled narrow angle glaucoma, myasthenia gravis, severe ulcerative colitis, or toxic megacolon as contraindications for anticholinergic bladder therapy\n* Use of drugs with adverse interactions with one of the study medications in the past 1 month, including potent CYP3A4 inhibitors, hepatic enzyme metabolism inducers, narrow therapeutic index drugs metabolized by CYP2D6, or intention to start taking one of these medications during the study treatment period\n* History of bladder surgery, invasive intra-vesical therapy, or bulk bladder injections in the past 3 months (more remote surgery will not be exclusionary), or intention to undergo one of these procedures in the study treatment period\n* Use of other specialized incontinence therapy (electrostimulation, pelvic physiotherapy, formal behavioral therapy overseen by certified practitioners) in the past 3 months (more remote therapy will not be exclusionary), or intention to undergo one of these procedures in the study treatment period\n* Inability to sign informed consent or complete questionnaires, interviews, or study testing in English\n* Other condition that would prevent the participant from completing study procedures, in the opinion of the investigators (e.g., uncontrolled psychosis)",true,"FEMALE","60 Years",{"count":21,"type":22},270,"ESTIMATED","INTERVENTIONAL",[25],"PHASE4","The TRIUMPH study is a randomized, double-blinded, 3-arm, parallel-group trial designed to compare the effects of anticholinergic bladder therapy versus a) beta-3-adrenergic agonist bladder therapy and b) no bladder pharmacotherapy on cognitive, urinary, and other aging-related functional outcomes in ambulatory older women with urgency-predominant urinary incontinence and either normal or mildly impaired cognitive function at baseline.",[28,29,30,31,32,33],"Urinary Incontinence, Urge","Urinary Incontinence","Overactive Bladder","Incontinence, Urge","Incontinence, Urinary","Incontinence","RECRUITING","2026-03-04",{"date":37,"type":38},"2026-03-06","ACTUAL",{"date":40,"type":38},"2022-10-04",{"date":42,"type":22},"2027-08-02",{"name":44,"class":45},"University of California, San Francisco","OTHER",2,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":18,"minAge":54,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":23,"phases":57,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":72},"100614403","efficacy-and-safety-of-7-millimeters-vaginal-radiofrequency-in-overactive-bladder-100614403","NCT07279142","Efficacy and Safety of 7 Millimeters Vaginal Radiofrequency in Overactive Bladder","HYPNOS","Inclusion Criteria:\n\n* age\\>18 years old\n* Subject is willing to provide Informed Consent, is geographically stable, understands the requirements for completing the bladder diary and is willing to comply with the required diary, follow-up visits, and testing schedules.\n* Urinary incontinence, predominant urgency incontinence, with moderate-severe overactive bladder, International Consultation on Incontinence Questionnaire - Overactibe Bladder Short Form (ICIQ-OABSS) score ≥6.\n* Ability and willingness to self-catheterize in case this is necessary.\n* With respect to their reproductive capacity must be post-menopausal or surgically sterile or willing to use a contraceptive method with a failure rate of less than 1% per year when used consistently and correctly from screening until the last follow up\n\nExclusion Criteria:\n\n* Pacemaker or internal defibrillator, or any other metallic or electronic implant anywhere in the body.\n* Any permanent implant or an injected chemical substance in the treatment area.\n* Superficial areas that have been injected with hyaluronic acid (HA)\u002Fcollagen\u002Ffat injections or other augmentation methods with bio-material during last 6 months.\n* Current or history of cancer, or current condition of any other type of cancer, or premalignant moles.\n* Severe concurrent conditions, such as cardiac disorders, sensory disturbances, epilepsy, uncontrolled hypertension, and liver or kidney diseases.\n* Pregnancy, the intention of pregnancy and nursing.\n* Impaired immune system due to immunosuppressive diseases such as Acquired Immunodeficency Syndrome (AIDS) and Human Immunodeficency Virus (HIV), autoimmune disorders, or use of immunosuppressive medications.\n* Patients with a history of diseases stimulated by heat, such as recurrent Herpes Simplex in the treatment area, may be treated only following a prophylactic regimen.\n* Poorly controlled endocrine disorders, such as diabetes or thyroid dysfunction and hormonal virilization.\n* Any active condition in the treatment area, such as sores, eczema, and rash.\n* History of vaginal disorders, keloids, abnormal wound healing.\n* History of bleeding coagulopathies or use of anticoagulants in the last 10 days, as per the practitioner's discretion.\n* Non-italian speakers\n* Severely impaired mobility or cognition\n* Spinal cord injury or advanced\u002Fsevere neurologic condition including Multiple Sclerosis, Parkinson's Disease\n* Repair of pelvic organ prolapse or incontinence procedure in the previous 6 months\n* Ongoing complications of prior anti-incontinence surgery\n* Received intravesical botulinum injection within the previous 12 months\n* History of an implanted nerve stimulator for incontinence\n* History of prior sling or vaginal mesh placement,\n* Previous diagnosis of interstitial cystitis, bladder cancer, or chronic pelvic pain\n* Current participation in any other conflicting interventional or OAB treatment study\n* Planning to become pregnant during the study period.\n* Pelvic radiation, history of pelvic radiation\n* Active urinary tract or vaginal infection\n* Anatomical conditions that would prevent the introduction and use of the device, in such as significant pelvic organ prolapse,\n* Current hydronephrosis or hydroureter\n* Bladder outflow obstruction\n* Active pelvic organ malignancy\n* Urethral obstruction\n* Urinary retention or prolonged catheter use\n* Less than 12 months post-partum or currently pregnant or plan to become pregnant in the following 12 months.\n* Untreated symptomatic urinary tract infection\n* Unevaluated hematuria\n* Medical instability\n* Allergy to anesthetics as Benzocaine\u002FLidocaine\u002FTetracaine Cream (BLT Cream) used in the study\n* Not available for follow-up in 6 months\n* Participation in other research trials that could influence results of this study","18 Years",{"count":56,"type":22},48,[58],"NA","The investigator hypothesizes that controlled delivery of low heat (45-50 Centigrade) to the sub-detrusor and detrusor muscle can ablate the autonomic nerve endings and control overactive bladder symptoms without causing significant damage to the surrounding structures. Low heat in such a manner is below urethral sensation and enables office treatment. The transvaginal approach is non-invasive and improves overactive bladder (OAB) symptoms and patients' quality of life. The investigator believes that the RF administration results could be equal or better for first-line treated patients compared to pharmacological refractory patients.",[61,31],"Overactive Bladder (OAB)","NOT_YET_RECRUITING","2025-12-10",{"date":65,"type":38},"2025-12-12",{"date":67,"type":22},"2025-12-16",{"date":69,"type":22},"2026-12-24",{"name":71,"class":45},"IRCCS San Raffaele",1,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":18,"minAge":54,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":23,"phases":82,"briefSummary":83,"conditions":84,"keywords":89,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":46},"100385978","phase-4-post-procedural-pain-associated-with-5-versus-20-intravesical-injections-of-onabotulinumtoxin-a-100385978","NCT04305743","Post-procedural Pain Associated With 5 Versus 20 Intravesical Injections of Onabotulinumtoxin A","Post-procedural Pain Associated With 5 Versus 20 Intravesical Injections of Onabotulinumtoxin A for Treatment of Overactive Bladder: a Multi-center Randomized Controlled Trial","Inclusion Criteria:\n\n* Women \\>=18 years of age with diagnosis of urinary urgency, urinary frequency, urgency urinary incontinence, overactive bladder.\n* Procedure scheduled in either the outpatient clinic or the operating room to be performed without use of sedation, general, or neuraxial anesthesia.\n\nExclusion Criteria:\n\n* Male gender.\n* Women \\\u003C18 years of age.\n* Non-English speaking.\n* Pregnancy (patient will self-report pregnancy).\n* Participant has symptoms of overactive bladder due to any known neurological reason (e.g. spinal cord injury, multiple sclerosis, cerebrovascular accident, Alzheimer's disease, Parkinson's disease, etc.)\n* Participant uses clean intermittent catheterization or indwelling catheter to manage urinary incontinence.\n* Participant has a history or current diagnosis of bladder cancer or other urothelial malignancy.\n* Participant has a known allergy or sensitivity to any botulinum toxin preparation.\n* Participant has any medical condition that may put her at increased risk with exposure to onabotulinumtoxin A, including diagnosed myasthenia gravis, Eaton-Lambert syndrome, or amyotrophic lateral sclerosis.\n* Participant is scheduled for administration of onabotulinumtoxin A with use of sedation, general, or neuraxial anesthesia.",{"count":81,"type":22},60,[25],"Currently, in clinical practice there has been no standardization in the number of injections a single dose of intradetrusor onabotulinumtoxin A is administered in. Given the increasing use of this treatment modality, the aim of this study is to compare outcomes for patients given a 100 unit dose of onabotulinumtoxin A split into 5 as compared to 20 injections for the treatment of overactive bladder or urgency urinary incontinence refractory to medical treatment.",[85,31,32,86,87,88],"Urinary Bladder, Overactive","Urinary Urge Incontinence","Urinary Frequency More Than Once at Night","Nocturia",[90,91,92,93,94],"overactive bladder","urgency urinary incontinence","onabotulinumtoxin","bladder","botox","2020-11-03",{"date":97,"type":38},"2020-11-05",{"date":99,"type":38},"2019-10-09",{"date":101,"type":22},"2021-06-01",{"name":103,"class":45},"University of South Florida"]